Artemis Investment Management LLP Lowers Stock Position in Becton Dickinson and Co (NYSE:BDX)

Artemis Investment Management LLP lowered its position in shares of Becton Dickinson and Co (NYSE:BDX) by 4.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 106,617 shares of the medical instruments supplier’s stock after selling 5,047 shares during the quarter. Artemis Investment Management LLP’s holdings in Becton Dickinson and were worth $28,971,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the business. Morgan Stanley raised its position in shares of Becton Dickinson and by 66.7% in the 2nd quarter. Morgan Stanley now owns 4,887,187 shares of the medical instruments supplier’s stock worth $1,231,621,000 after purchasing an additional 1,955,095 shares during the last quarter. Nuveen Asset Management LLC raised its position in shares of Becton Dickinson and by 12,995.3% in the 2nd quarter. Nuveen Asset Management LLC now owns 1,429,875 shares of the medical instruments supplier’s stock worth $360,343,000 after purchasing an additional 1,418,956 shares during the last quarter. Massachusetts Financial Services Co. MA raised its position in shares of Becton Dickinson and by 33.8% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 2,152,328 shares of the medical instruments supplier’s stock worth $544,452,000 after purchasing an additional 543,512 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Becton Dickinson and by 2.3% in the 2nd quarter. Vanguard Group Inc. now owns 23,018,011 shares of the medical instruments supplier’s stock worth $5,800,769,000 after purchasing an additional 520,350 shares during the last quarter. Finally, Stonehage Fleming Financial Services Holdings Ltd purchased a new position in shares of Becton Dickinson and in the 2nd quarter worth about $101,966,000. 84.46% of the stock is owned by institutional investors and hedge funds.

Several research firms have recently issued reports on BDX. Morgan Stanley lifted their price target on Becton Dickinson and from $261.00 to $287.00 and gave the stock an “equal weight” rating in a research report on Tuesday, December 17th. Barclays lowered Becton Dickinson and from an “overweight” rating to an “equal weight” rating and set a $275.00 price target for the company. in a research report on Wednesday, January 8th. KeyCorp lowered their price target on Becton Dickinson and from $262.00 to $256.00 and set an “overweight” rating for the company in a research report on Wednesday, November 13th. Stifel Nicolaus lifted their price target on Becton Dickinson and from $275.00 to $295.00 and gave the stock a “buy” rating in a research report on Monday, December 16th. Finally, JPMorgan Chase & Co. lifted their price target on Becton Dickinson and from $285.00 to $300.00 and gave the stock an “overweight” rating in a research report on Friday, December 20th. Six research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. Becton Dickinson and presently has an average rating of “Buy” and an average target price of $277.70.

In related news, EVP Patrick Kaltenbach sold 339 shares of Becton Dickinson and stock in a transaction dated Thursday, December 12th. The stock was sold at an average price of $263.23, for a total value of $89,234.97. Following the completion of the sale, the executive vice president now directly owns 19,546 shares in the company, valued at approximately $5,145,093.58. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Vincent A. Forlenza sold 33,365 shares of the business’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $271.28, for a total value of $9,051,257.20. Following the sale, the chief executive officer now owns 254,312 shares of the company’s stock, valued at $68,989,759.36. The disclosure for this sale can be found here. Insiders sold a total of 91,231 shares of company stock valued at $24,787,690 over the last quarter. 0.12% of the stock is owned by corporate insiders.

NYSE BDX opened at $275.96 on Wednesday. Becton Dickinson and Co has a one year low of $221.47 and a one year high of $277.45. The stock has a 50-day moving average of $267.48 and a 200 day moving average of $255.96. The company has a market capitalization of $74.23 billion, a price-to-earnings ratio of 23.63, a PEG ratio of 1.96 and a beta of 1.07. The company has a debt-to-equity ratio of 0.86, a quick ratio of 0.72 and a current ratio of 1.18.

Becton Dickinson and (NYSE:BDX) last released its quarterly earnings data on Tuesday, November 5th. The medical instruments supplier reported $3.31 EPS for the quarter, topping the consensus estimate of $3.30 by $0.01. Becton Dickinson and had a return on equity of 15.52% and a net margin of 6.84%. The company had revenue of $4.58 billion during the quarter, compared to the consensus estimate of $4.57 billion. During the same period last year, the company earned $2.93 EPS. Becton Dickinson and’s revenue for the quarter was up 4.1% on a year-over-year basis. On average, equities analysts predict that Becton Dickinson and Co will post 12.57 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, December 31st. Investors of record on Tuesday, December 10th were issued a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 1.15%. This is an increase from Becton Dickinson and’s previous quarterly dividend of $0.77. The ex-dividend date was Monday, December 9th. Becton Dickinson and’s dividend payout ratio (DPR) is presently 27.05%.

Becton Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Further Reading: Hedge Funds Explained

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.